152 related articles for article (PubMed ID: 3909671)
21. Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis.
Granito A; Muratori P; Muratori L; Pappas G; Cassani F; Worthington J; Ferri S; Quarneti C; Cipriano V; de Molo C; Lenzi M; Chapman RW; Bianchi FB
Aliment Pharmacol Ther; 2007 Sep; 26(6):831-8. PubMed ID: 17767467
[TBL] [Abstract][Full Text] [Related]
22. [Parietal cell antibodies in primary biliary cirrhosis: pathogenetic or diagnostic significance?].
Wirth HP; Meyenberger C; Ammann R; Blum HE
Schweiz Med Wochenschr; 1994 May; 124(19):816-20. PubMed ID: 8209205
[TBL] [Abstract][Full Text] [Related]
23. [Primary biliary cirrhosis: therapeutic trial using plasma exchange and immunosuppression. Preliminary results].
Rifle G; Mousson C; Hillon P; Marceau M; Chalopin JM; Tanter Y
Ann Med Interne (Paris); 1988; 139 Suppl 1():32-4. PubMed ID: 3247987
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of immune disturbances and chronic liver disease in family members of patients with primary biliary cirrhosis.
Bittencourt PL; Farias AQ; Abrantes-Lemos CP; Goncalves LL; Goncalves PL; Magalhães EP; Carrilho FJ; Laudanna AA; Cançado EL
J Gastroenterol Hepatol; 2004 Aug; 19(8):873-8. PubMed ID: 15242489
[TBL] [Abstract][Full Text] [Related]
25. Pilot study of low dose oral methotrexate treatment for primary biliary cirrhosis.
Bergasa NV; Jones A; Kleiner DE; Rabin L; Park Y; Wells MC; Hoofnagle JH
Am J Gastroenterol; 1996 Feb; 91(2):295-9. PubMed ID: 8607496
[TBL] [Abstract][Full Text] [Related]
26. A prospective trial of D-penicillamine in primary biliary cirrhosis.
Matloff DS; Alpert E; Resnick RH; Kaplan MM
N Engl J Med; 1982 Feb; 306(6):319-26. PubMed ID: 7033789
[TBL] [Abstract][Full Text] [Related]
27. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
[TBL] [Abstract][Full Text] [Related]
29. [Clinical and pathological study of autoimmune hepatopathy].
Han Y; Zhang W; Chen J; Zhou H; Wang L
Zhonghua Gan Zang Bing Za Zhi; 2001 Jul; 9 Suppl():82-4. PubMed ID: 11509150
[TBL] [Abstract][Full Text] [Related]
30. Evolution from primary biliary cirrhosis to primary biliary cirrhosis/autoimmune hepatitis overlap syndrome.
Twaddell WS; Lefkowitch J; Berk PD
Semin Liver Dis; 2008 Feb; 28(1):128-34. PubMed ID: 18293283
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of C3b-binding in chronic liver diseases.
Hautanen A; Salaspuro MP
Scand J Gastroenterol; 1981; 16(4):505-12. PubMed ID: 7323688
[TBL] [Abstract][Full Text] [Related]
32. Increased serum IgM class anti-lipid A antibody and therapeutic effect of ursodeoxycholic acid in primary biliary cirrhosis.
Ide T; Sata M; Nakano H; Suzuki H; Tanikawa K
Hepatogastroenterology; 1997; 44(18):1569-73. PubMed ID: 9427024
[TBL] [Abstract][Full Text] [Related]
33. No prognostic significance of antimitochondrial antibody profile testing in primary biliary cirrhosis.
Vleggaar FP; van Buuren HR
Hepatogastroenterology; 2004; 51(58):937-40. PubMed ID: 15239218
[TBL] [Abstract][Full Text] [Related]
34. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
[TBL] [Abstract][Full Text] [Related]
35. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.
Heathcote EJ; Cauch-Dudek K; Walker V; Bailey RJ; Blendis LM; Ghent CN; Michieletti P; Minuk GY; Pappas SC; Scully LJ
Hepatology; 1994 May; 19(5):1149-56. PubMed ID: 8175136
[TBL] [Abstract][Full Text] [Related]
36. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
[TBL] [Abstract][Full Text] [Related]
37. [Study on association of BAFF receptors gene expression and primary biliary cirrhosis].
Liang Y; Yang ZX; Zhu Y; Wang Y; Zeng XM; Deng AM; Zhong RQ
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(2):128-30. PubMed ID: 17418023
[TBL] [Abstract][Full Text] [Related]
38. Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation.
Balan V; Batts KP; Porayko MK; Krom RA; Ludwig J; Wiesner RH
Hepatology; 1993 Dec; 18(6):1392-8. PubMed ID: 8244263
[TBL] [Abstract][Full Text] [Related]
39. Transitions between variant forms of primary biliary cirrhosis during long-term follow-up.
Lindgren S; Glaumann H; Almer S; Bergquist A; Björnsson E; Broomé U; Danielsson A; Lebrun B; Prytz H; Olsson R
Eur J Intern Med; 2009 Jul; 20(4):398-402. PubMed ID: 19524182
[TBL] [Abstract][Full Text] [Related]
40. Primary biliary cirrhosis. High proportions of B cells in blood and liver tissue produce anti-mitochondrial antibodies of several Ig classes.
Björkland A; Lööf L; Mendel-Hartvig I; Tötterman TH
J Immunol; 1994 Sep; 153(6):2750-7. PubMed ID: 8077679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
